{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:28:12Z","timestamp":1791358092661,"version":"4.3.1"},"reference-count":46,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) is the most common type of dementia, causing progressive decline of memory, thinking, and behavior, impairing daily functioning. Early AD (eAD) includes mild cognitive impairment (MCI) due to AD and mild AD dementia. Objective: The aim of this study was to investigate symptomatic treatment prevalence and treatment patterns in eAD. Methods: Embase, MEDLINE, and EBM Reviews were searched in November 2021 for observational studies reporting symptomatic treatment patterns in eAD. The range of patients receiving treatment was collated. Risk of bias was assessed using the Joanna Briggs Institute (JBI) prevalence tool. Two independent reviewers screened the records, one performed data extraction and quality assessment while a second checked. Results: Twenty-one studies (prospective and retrospective cohorts, cross-sectional studies, and a survey) were included. Population size ranged from 23 to 2,028. Worldwide, 18 to 35% of patients diagnosed with MCI due to AD received any AChE inhibitor (three studies; n\u200a=\u200a631), 7 to 8% memantine (two studies; n\u200a=\u200a229), and 9% combination therapy (one study; n\u200a=\u200a402). Patients receiving no treatment ranged from 41 to 54% (two studies; n\u200a=\u200a733). Worldwide, in mild AD dementia patients, 13 to 89% received any AChE inhibitor (six studies; n\u200a=\u200a3,715), 1 to 21% memantine (five studies, n\u200a=\u200a3,527), and 0.4 to 39% combination therapy (four studies, n\u200a=\u200a3,018). Patients receiving no treatment ranged from 9 to 26% (five studies, n\u200a=\u200a4,073). Conclusion: Limitations in reporting led to unclear risk of bias. The results reveal a pattern of use of symptomatic treatment in eAD beyond approved labels and highlights the opportunity for new consensus guidelines to inform clinical practice.<\/jats:p>","DOI":"10.3233\/jad-220471","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T10:46:48Z","timestamp":1668768408000},"page":"151-167","source":"Crossref","is-referenced-by-count":11,"title":["Real-World Use of Symptomatic Treatments in Early Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"91","author":[{"given":"Maria Jo\u00e3o","family":"Garcia","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Leadley","sequence":"additional","affiliation":[{"name":"Mtech Access, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Lang","sequence":"additional","affiliation":[{"name":"Mtech Access, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Ross","sequence":"additional","affiliation":[{"name":"Mtech Access, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Vinand","sequence":"additional","affiliation":[{"name":"Mtech Access, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[{"name":"University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Gsteiger","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220471_ref1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Nichols","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220471_ref2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer\u2019s disease facts and figures","volume":"16","author":"Alzheimer\u2019s Association","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220471_ref3","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.37765\/ajmc.2020.88481","article-title":"Current and evolving treatment strategies for the Alzheimer disease continuum","volume":"26","author":"Marasco","year":"2020","journal-title":"Am J Manag Care"},{"key":"10.3233\/JAD-220471_ref4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.3233\/JAD-220471_ref5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Petersen","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-220471_ref6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JAD-200786","article-title":"Severity distribution of Alzheimer\u2019s disease dementia and mild cognitive impairment in the Framingham Heart Study","volume":"79","author":"Yuan","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220471_ref9","first-page":"1403","article-title":"Treatment of Alzheimer disease","volume":"83","author":"Winslow","year":"2011","journal-title":"Am Fam Physician"},{"issue":"Suppl 3","key":"10.3233\/JAD-220471_ref10","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1016\/j.jval.2018.09.1983","article-title":"Pharmaceutical treatment of mild Alzheimer\u2019s disease in Germany - results from a delphi panel","volume":"21","author":"Kohlscheen","year":"2018","journal-title":"Value Health"},{"key":"10.3233\/JAD-220471_ref11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-019-0525-9","article-title":"Use of mild cognitive impairment and prodromal AD\/MCI due to AD in clinical care: A European survey","volume":"11","author":"Bertens","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220471_ref12","volume-title":"Presented at Alzheimer\u2019s Association International Conference (AAIC)","author":"Lin","year":"2018"},{"key":"10.3233\/JAD-220471_ref13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220471_ref16","first-page":"25","article-title":"Pragmatic literature review: Pharmacological treatment patterns in early Alzheimer\u2019s disease [Unpublished Work]","author":"Joao Garcia","year":"2021","journal-title":"F. Hoffmann-La Roche Ltd"},{"key":"10.3233\/JAD-220471_ref17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.3233\/JAD-220471_ref19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence","volume":"3","author":"Munn","year":"2014","journal-title":"Int J Health Policy Manag"},{"key":"10.3233\/JAD-220471_ref20","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.3233\/JAD-220471_ref21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2010.343","article-title":"Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer\u2019s disease neuroimaging initiative","volume":"68","author":"Schneider","year":"2011","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-220471_ref22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YIC.0000000000000205","article-title":"Use of antidementia drugs in German patients with Alzheimer\u2019s disease","volume":"33","author":"Hessmann","year":"2018","journal-title":"Int Clin Psychopharmacol"},{"key":"10.3233\/JAD-220471_ref23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2016.04.007","article-title":"Mild cognitive impairment in Parkinson\u2019s disease versus Alzheimer\u2019s disease","volume":"27","author":"Besser","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JAD-220471_ref24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s12325-019-01213-z","article-title":"Alzheimer\u2019s treatment: Real-world physician behavior across countries","volume":"37","author":"Podhorna","year":"2020","journal-title":"Adv Ther"},{"key":"10.3233\/JAD-220471_ref25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/WAD.0b013e318299d096","article-title":"The effect of APOE epsilon4 allele on cholinesterase inhibitors in patients with Alzheimer disease: Evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging","volume":"28","author":"Wang","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-220471_ref26","doi-asserted-by":"crossref","first-page":"e029663","DOI":"10.1136\/bmjopen-2019-029663","article-title":"How many patients are eligible for disease-modifying treatment in Alzheimer\u2019s disease? A French national observational study over 5 years","volume":"9","author":"Epelbaum","year":"2019","journal-title":"BMJ Open"},{"key":"10.3233\/JAD-220471_ref27","first-page":"85","article-title":"Treatment with vitamin D and slowing of progression to severe stage of Alzheimer\u2019s disease","volume":"25","author":"Chaves","year":"2014","journal-title":"Rev Argent Neurol Psiquiatr"},{"key":"10.3233\/JAD-220471_ref28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40266-017-0446-x","article-title":"Trends in the prescription and long-term utilization of antidementia drugs among patients with Alzheimer\u2019s disease in Spain: A cohort study using the registry of dementias of Girona","volume":"34","author":"Calvo-Perxas","year":"2017","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-220471_ref29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-122392","article-title":"The GERAS study: A prospective observational study of costs and resource use in community dwellers with Alzheimer\u2019s disease in three European countries - study design and baseline findings","volume":"36","author":"Wimo","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220471_ref30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jval.2019.04.1937","article-title":"A real-world evidence analysis of associations among costs, quality of life, and disease-severity indicators of Alzheimer\u2019s disease in Thailand","volume":"22","author":"Kongpakwattana","year":"2019","journal-title":"Value Health"},{"key":"10.3233\/JAD-220471_ref31","first-page":"55","article-title":"Costs and resource use associated with Alzheimer\u2019s disease in Italy: Results from an observational study","volume":"5","author":"Bruno","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-220471_ref32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13195-018-0360-4","article-title":"Representativeness of European clinical trial populations in mild Alzheimer\u2019s disease dementia: A comparison of 18-month outcomes with real-world data from the GERAS observational study","volume":"10","author":"Reed","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220471_ref33","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1017\/S1041610215000289","article-title":"Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer\u2019s disease","volume":"27","author":"Droogsma","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-220471_ref34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/156720510791162430","article-title":"Cross sectional observational study on the societal costs of Alzheimer\u2019s disease","volume":"7","author":"Mesterton","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-220471_ref35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13195-016-0174-1","article-title":"Mild versus moderate stages of Alzheimer\u2019s disease: Three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy","volume":"8","author":"Wattmo","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220471_ref36","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1017\/S1041610217001211","article-title":"Costs and quality of life in community-dwelling patients with Alzheimer\u2019s disease in Spain: Results from the GERAS II observational study","volume":"29","author":"Olazaran","year":"2017","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-220471_ref37","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3233\/JAD-201357","article-title":"Assessment of a potential synergistic effect of Souvenaid R in mild Alzheimer\u2019s disease patients on treatment with acetylcholinesterase inhibitors: An observational, non-interventional study","volume":"80","author":"Vinuela","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220471_ref38","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1017\/S104161021600123X","article-title":"Comparison of neuropsychological and functional outcomes in Alzheimer\u2019s disease patients with good or bad response to a cognitive stimulation treatment: A retrospective analysis","volume":"28","author":"Martinez-Moreno","year":"2016","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-220471_ref39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0325-0938(10)70005-2","article-title":"[Naturalist observational study on effectiveness of drug treatment of a cohort of patients with Alzheimer type dementia]","volume":"2","author":"Rojas","year":"2010","journal-title":"Neurologia Argentina"},{"key":"10.3233\/JAD-220471_ref40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/11315320-000000000-00000","article-title":"Safety\/Tolerability and efficacy of rivastigmine in Taiwanese patients with Alzheimer\u2019s disease: A prospective post-marketing surveillance study","volume":"29","author":"Chiu","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.3233\/JAD-220471_ref41","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3233\/JAD-150092","article-title":"Use of anti-dementia drugs in relation to change in cognition, behavior, and functioning in Alzheimer\u2019s disease over a three-year period: Kuopio ALSOVA study","volume":"48","author":"Tormalehto","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220471_ref42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/13554790903193174","article-title":"Alzheimer\u2019s disease neuropathologic changes in semantic dementia","volume":"16","author":"Chow","year":"2010","journal-title":"Neurocase"},{"key":"10.3233\/JAD-220471_ref43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CEOR.S146788","article-title":"Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer\u2019s disease in Japan","volume":"10","author":"Montgomery","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.3233\/JAD-220471_ref44","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-148-5-200803040-00008","article-title":"Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians","volume":"148","author":"Qaseem","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-220471_ref47","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jalz.2010.07.005","article-title":"Alzheimer\u2019s disease management guideline: Update 2008","volume":"7","author":"Segal-Gidan","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220471_ref48","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/alz.12105","article-title":"Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia","volume":"16","author":"Ismail","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220471_ref49","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1468-1331.2010.03040.x","article-title":"EFNS guidelines for the diagnosis and management of Alzheimer\u2019s disease","volume":"17","author":"Hort","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-220471_ref50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0269881116680924","article-title":"Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology","volume":"31","author":"O\u2019Brien","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"Suppl 1","key":"10.3233\/JAD-220471_ref52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002512-200522001-00002","article-title":"Guidelines for the treatment of Alzheimer\u2019s disease from the Italian Association of Psychogeriatrics","volume":"22","author":"Caltagirone","year":"2005","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-220471_ref55","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer\u2019s disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-220471_ref56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12916-021-02151-w","article-title":"Risk of bias in observational studies using routinely collected data of comparative effectiveness research: A meta-research study","volume":"19","author":"Nguyen","year":"2021","journal-title":"BMC Med"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:57Z","timestamp":1777370877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220471"}},"subtitle":[],"editor":[{"given":"Elzbieta","family":"Kuzma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":46,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-220471","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]}}}